Elacestrant: all 30 studies that test it

Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerRecruitingNCT07766018Phase 2
• Medical Imaging to Re-evaluate Elacestrant Clinical UsageNot yet recruitingNCT07753954Phase 2
• Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial CancerNot yet recruitingNCT07634601Phase 2
• Elacestrant in Advanced Triple Positive Breast CancerRecruitingNCT07612215Phase 1/2
• Ph 2 Elacestrant in ER Positive Uterine SarcomasRecruitingNCT07467772Phase 2
• Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)RecruitingNCT07395336Phase 2
• Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCRecruitingNCT07242352Phase 3
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)RecruitingNCT07222215Phase 2
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerRecruitingNCT07198724Phase 1/2
• Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR RadiotherapyNot yet recruitingNCT07005882Phase 2
• Circulating Tumor DNARecruitingNCT06923527Phase 2
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceRecruitingNCT06492616Phase 3
• Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerRecruitingNCT06201234Phase 2
• DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingNCT06075953Phase 2
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingNCT06062498Phase 2
• Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerRecruitingNCT05982093Phase 2
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingNCT05512364Phase 3
• Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingNCT05386108Phase 1/2
• Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast CancerTerminatedNCT05618613Phase 1/2Results posted
• Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerCompletedNCT03778931Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor SymptomsTerminatedNCT02653417Phase 2Results posted
• A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal WomenCompletedNCT00875420Phase 2Results posted
• A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast CancerWithdrawnNCT06938711Phase 1/2
• A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic FunctionCompletedNCT06126575Phase 1
• Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingNCT05826964Phase 2
• ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyActive, not recruitingNCT05596409Phase 2
• Elacestrant in Preoperative Setting, a Window of Opportunity StudyCompletedNCT04797728Early Phase 1
• Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast CancerTerminatedNCT04791384Phase 1/2
• Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast CancerCompletedNCT02650817Phase 1
• A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast CancerCompletedNCT02338349Phase 1

← Elacestrant overview